Leveraging cryoablation and checkpoint inhibitors for high-risk triple negative breast cancer.

Saved in:

Bibliographic Details
Title:	Leveraging cryoablation and checkpoint inhibitors for high-risk triple negative breast cancer.
Authors:	Sardela de Miranda F; Department of Surgery, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, United States.; Department of Immunology and Molecular Microbiology, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, United States.; Breast Center of Excellence, Texas Tech University Health Sciences Center, Lubbock, TX, United States., Castro M; Department of Surgery, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, United States.; Breast Center of Excellence, Texas Tech University Health Sciences Center, Lubbock, TX, United States., Remmert N; Department of Surgery, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, United States.; Breast Center of Excellence, Texas Tech University Health Sciences Center, Lubbock, TX, United States., Singh SP; Department of Surgery, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, United States.; Breast Center of Excellence, Texas Tech University Health Sciences Center, Lubbock, TX, United States.; Department of Internal Medicine, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, United States., Layeequr Rahman R; Department of Surgery, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, United States.; Breast Center of Excellence, Texas Tech University Health Sciences Center, Lubbock, TX, United States., Melkus MW; Department of Surgery, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, United States.; Breast Center of Excellence, Texas Tech University Health Sciences Center, Lubbock, TX, United States.
Source:	Frontiers in immunology [Front Immunol] 2023 Oct 04; Vol. 14, pp. 1258873. Date of Electronic Publication: 2023 Oct 04 (Print Publication: 2023).
Publication Type:	Journal Article; Review; Research Support, Non-U.S. Gov't
Journal Info:	Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	1664-3224
DOI:	10.3389/fimmu.2023.1258873